Mineralys Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on Tuesday, November 7, 2023
31 Outubro 2023 - 5:05PM
Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage
biopharmaceutical company focused on developing medicines to target
hypertension, chronic kidney disease (CKD) and other diseases
driven by abnormally elevated aldosterone, today announced it will
report its financial results from the third quarter ended September
30, 2023, after the financial markets close on Tuesday, November 7,
2023.
Tuesday, November 7th
@ 4:30 p.m. ET
Domestic: |
1-888-886-7786 |
|
|
International: |
1-416-764-8658 |
|
|
Conference ID: |
27015887 |
|
|
Webcast: |
Link |
|
|
If you would like a call back, please click this link, which
will be made active 15 minutes prior to the scheduled start time. A
live webcast of the conference call may be found here. A replay of
the call will be available on the “News & Events” page in the
Investor Relations section of the Mineralys Therapeutics
website.
About Mineralys TherapeuticsMineralys
Therapeutics is a clinical-stage biopharmaceutical company focused
on developing medicines to target hypertension, chronic kidney
disease and other diseases driven by abnormally elevated
aldosterone. Its initial product candidate, lorundrostat, is a
proprietary, orally administered, highly selective aldosterone
synthase inhibitor that Mineralys Therapeutics is developing for
cardiorenal conditions affected by abnormally elevated aldosterone,
including hypertension and CKD. Mineralys is based in Radnor,
Pennsylvania, and was founded by Catalys Pacific. For more
information, please visit https://mineralystx.com. Follow
Mineralys on LinkedIn and Twitter.
Contact:Investor
Relationsinvestorrelations@mineralystx.com
Media RelationsTom WeibleElixir
Health Public RelationsPhone: (1) 515-707-9678Email:
tweible@elixirhealthpr.com
Mineralys Therapeutics (NASDAQ:MLYS)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Mineralys Therapeutics (NASDAQ:MLYS)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024